Physician profile
Sarah E Plummer
NPI 1154694974
$910.28
in general payments reported to CMS, 2019-2025
20 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.86 · 2022: $155 · 2023: $75.56 · 2024: $395 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $187.92 | 2024-2025 | Prevena, V.A.C. Dermatac, Promogran Prisma |
| Incyte Corporation | $175.13 | 2022-2025 | Jakafi, Zynyz, Monjuvi |
| Medtronic, INC. | $81.36 | 2022-2023 | Signia |
| Vertex Pharmaceuticals Incorporated | $41.42 | 2025 | |
| Seagen INC. | $38.85 | 2022 | |
| Merck Sharp & Dohme LLC | $38.31 | 2024 | Keytruda |
| Genentech USA, INC. | $34.89 | 2025 | Itovebi |
| Takeda Pharmaceuticals U.S.A., INC. | $32.58 | 2024 | Fruzaqla, Alunbrig |
| Intuitive Surgical, INC. | $32.48 | 2024 | |
| Novartis Pharmaceuticals Corporation | $28.38 | 2025 | |
| Beone Medicines USA, INC. | $28.10 | 2025 | Tevimbra, Brukinsa |
| Beigene USA, INC. | $27.61 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $26.25 | 2025 | Orgovyx |
| Pfizer INC. | $23.53 | 2024 | |
| Genzyme Corporation | $21.74 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $20.59 | 2023 | Kyprolis, Blincyto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.48 | 2023 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $18.71 | 2021 | |
| Baxter Healthcare | $16.80 | 2024 | Tisseel |
| Myovant Sciences INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.